Marker Therapeutics, Inc. (MRKR)
| Previous Close | 3.7600 |
| Open | 3.9400 |
| Bid | 3.1400 x 200 |
| Ask | 4.9900 x 200 |
| Day's Range | 3.8000 - 4.4000 |
| 52 Week Range | 2.4400 - 6.1600 |
| Volume | |
| Avg. Volume | 36,314 |
| Market Cap | 38.278M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1500 |
| Earnings Date | Aug 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.75 |
Simply Wall St.US Penny Stocks To Consider In October 2024
Major U.S. stock indexes have seen a downturn recently, with the Dow Jones, S&P 500, and Nasdaq Composite all experiencing declines amid rising Treasury yields and mixed earnings reports. Despite these fluctuations, there remains potential in the market for those willing to explore beyond established giants. Penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at attractive price points when backed by strong fundamentals and solid...
- TipRanks
Marker Therapeutics price target raised to $19 from $11 at Ladenburg
Ladenburg analyst Aydin Huseynov raised the firm’s price target on Marker Therapeutics (MRKR) to $19 from $11 and keeps a Buy rating on the shares. Ladenburg is becoming more confident in seeing additional responses among post-CAR-T diffuse large B-cell lymphoma patients treated with neldaleucel by Q4, and tells investors in a research note that Marker’s management appears focused on gathering a comprehensive dataset with sufficient statistical and clinical significance, which would support adva
